Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Rituximab
60%
Doxorubicin
52%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
43%
Vincristine
37%
Prednisolone
37%
Cyclophosphamide
31%
Survival Rate
29%
Overall Survival
25%
Nonhodgkin Lymphoma
21%
Soluble Interleukin 2 Receptor
17%
Pirarubicin
16%
Peripheral T Cell Lymphoma
16%
Tumor Necrosis Factor Receptor 2
15%
Kynurenine
12%
Neoplasm
11%
Adverse Event
10%
Remission
9%
Progression Free Survival
9%
Biological Marker
8%
Monoclonal Antibody
8%
Stenosis
7%
Ifosfamide
7%
Adenocarcinoma
7%
Interleukin 18
7%
Methotrexate
7%
Hematologic Malignancy
7%
Chemotherapy
7%
Biapenem
7%
Stomach Cancer
7%
Lymphadenopathy
7%
Progranulin
7%
First-Line Chemotherapy
7%
Carboplatin
7%
B Cell Lymphoma
7%
Febrile Neutropenia
7%
Malignant Neoplasm
7%
Lymphoma
7%
Survivin
7%
Seminoma
7%
Hydronephrosis
7%
Etoposide
7%
Methylprednisolone
7%
Ascites
7%
Kynurenic Acid
7%
3 Hydroxykynurenine
7%
Anthracycline
7%
Cardiotoxicity
5%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
66%
Neoplasm
40%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
34%
Non-Hodgkin Lymphoma
29%
Prognostic Factor
27%
Overall Survival
27%
Rituximab
25%
Soluble Interleukin 2 Receptor
23%
CHOP
22%
Survival Rate
22%
Doxorubicin
21%
Follicular Lymphoma
20%
International Prognostic Index
17%
Peripheral T-Cell Lymphoma
17%
Follicular Dendritic Cells
16%
Tumor Necrosis Factor Receptor 2
15%
Endoscopic Ultrasound Guided Fine Needle Biopsy
15%
Fine-Needle Aspiration
15%
Etoposide
15%
Lymphoma
13%
Elderly Patient
10%
Polyethylene Glycol
10%
Stomach Cancer
10%
Vincristine
10%
Cyclophosphamide
10%
Prednisolone
10%
Pirarubicin
9%
Acute Myeloid Leukemia
9%
Endoscopy
9%
Febrile Neutropenia
9%
MALT Lymphoma
9%
B-Cell Lymphoma
9%
Percutaneous Endoscopic Gastrostomy
9%
Gastrostomy
8%
Clinical Stage
8%
Multivariate Analysis
8%
Immunoglobulin G4
7%
Methylprednisolone
7%
First-Line Chemotherapy
7%
Cytokeratin
7%
Duodenum Ulcer
7%
Cytokine
7%
Mantle Cell Lymphoma
7%
Methotrexate
7%
Granulocyte Colony Stimulating Factor
7%
Sarcopenia
7%
Interleukin 4
7%
Cytarabine
7%
Low Drug Dose
7%
Ifosfamide
7%
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
67%
Rituximab
30%
Prednisolone
27%
Soluble interleukin-2 Receptor (sIL-2R)
25%
Clinical Outcomes
25%
Peripheral T-cell Lymphoma
24%
Doxorubicin
24%
Phase II Study
23%
Cyclophosphamide
22%
R-THP-COP
21%
Adriamycin
19%
Elderly Patients
18%
Prognostic Factors
18%
International Prognostic Index
18%
Aggressive non-Hodgkin Lymphoma
17%
Non-Hodgkin Lymphoma
17%
Pirarubicin
16%
Serum Interleukins
15%
Overall Survival Rate
11%
R-CHOP
10%
Overall Survival
9%
Independent Prognostic Factor
9%
Colonoscopy
9%
Low-grade Lymphoma
8%
Complete Remission
7%
Clinical Significance
7%
Colorectal Neoplasms
7%
Unfavorable Outcome
7%
Male Patients
7%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
7%
Soluble Tumor Necrosis Factor Receptor 2
7%
Mantle Cell Lymphoma
7%
Cell Features
7%
R-CHOP Regimen
7%
Fibroblastic Reticular Cell Tumor
7%
Biliary Dilation
7%
Soluble Fas
7%
Cell Networks
7%
Jejunoileal
7%
Soluble CD27
7%
Interleukin-18 (IL-18)
7%
Follicular Variant
7%
Interleukin-4 (IL-4)
7%
Monoclonal Gammopathy of Undetermined Significance
7%
Type I Cryoglobulinemia
7%
Indolent Lymphoma
7%
Lymphoma Model
7%
Plasmablastic Lymphoma
7%
Novel Antibodies
7%
Unique Pattern
7%